TG Therapeutics Inc. (TGTX)
NASDAQ: TGTX
· Real-Time Price · USD
34.97
2.60 (8.03%)
At close: Sep 22, 2025, 3:59 PM
35.59
1.77%
Pre-market: Sep 23, 2025, 06:56 AM EDT
8.03% (1D)
| Bid | 33.26 |
| Market Cap | 5.55B |
| Revenue (ttm) | 454.07M |
| Net Income (ttm) | 60.46M |
| EPS (ttm) | 0.38 |
| PE Ratio (ttm) | 92.03 |
| Forward PE | 18.18 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 35.67 |
| Volume | 3,381,157 |
| Avg. Volume (20D) | 2,152,546 |
| Open | 32.50 |
| Previous Close | 32.37 |
| Day's Range | 32.29 - 35.06 |
| 52-Week Range | 21.16 - 46.48 |
| Beta | 1.88 |
| Ex-Dividend Date | n/a |
About TGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsTG Therapeutics Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+6.66%
TG Therapeutic shares are trading higher after the...
Unlock content with
Pro Subscription
1 month ago
-17.99%
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS and sales.
1 month ago · fool.com
TG Therapeutics Q2 Revenue Up 91%TG Therapeutics Q2 Revenue Up 91%
3 months ago · seekingalpha.com
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-CelTG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development ...